Latest News and Press Releases

CAMBRIDGE, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...

CAMBRIDGE, Mass., Oct. 8, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...

CAMBRIDGE, Mass., Sept. 3, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas P. Mathers, Chief Executive Officer, will provide a corporate overview at...

Enrolled the first patient in the SAMURAI trial, the first of two phase 3 pivotal clinical trials investigating lasmiditan for the acute treatment of migraine headaches Priced its initial...

CAMBRIDGE, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...

BURLINGTON, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. ("CoLucid") (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product...

First Patient Randomized in SAMURAI STUDY Trial Being Conducted Under Special Protocol Assessment Agreement with FDA BURLINGTON, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- CoLucid...